Focus: Sintetica is a Swiss biotech (founded 1921) specializing in analgesics and anesthetics with a secondary focus on ophthalmology, operating as a mid-size organization with 201-500 employees.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Sintetica offers stability and niche expertise in anesthetics, but opaque financials and modest hiring activity make it best suited for candidates seeking specialized experience over rapid career escalation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Portfolio anchor with 5 Phase 2–3 trials across multiple indications and formulations driving clinical validation
Help build intelligence for Sintetica
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sintetica's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary pain management program in early development (Phase 1–2) with limited clinical traction
Recent peer-reviewed publications with author affiliations at this company
Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection.
Prospective Study of the Relative Abundance of Antimicrobial Resistance Genes in Escherichia coli O157:H7 Obtained from Chicken Carcasses from Local Markets in Lima, Peru.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo